Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Phase I/II Study of ABT-888 (Veliparib) in combination with 5-Fluorouracil and Oxaliplatin (modified FOLFOX6) in Patients with Metastatic Pancreatic Cancer

Summary

The purpose of this study is to test the efficacy of the PARP inhibitor ABT-888 and mFOLFOX-6 for patients with metastatic pancreatic cancer.

General Information

NCT#: NCT01489865
Study ID: 2009-608
Trial Phase: Phase I/II

Trial Sponsor: Abbott Laboratories, Georgetown University
Therapies Used in This Trial: Fluorouracil, Oxaliplatin, Leucovorin, Veliparib, FOLFOX

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search